MODAG starts first-in-human Phase 1 clinical trial for Anle138b
Category: #health  By Pankaj Singh  Date: 2019-12-19
  • share
  • Twitter
  • Facebook
  • LinkedIn

MODAG starts first-in-human Phase 1 clinical trial for Anle138b

MODAG has announced the start of clinical trial and recruitment for a first-in-human Phase 1 study of Anle 138b in healthy volunteers. Reportedly, the compound is being fostered for the Multiple System Atrophy (MSA)’s treatment with the capability to be used in other synucleinopathies, including Parkinson’s disease. Embellishing the Company’s patent estate for anle138b to exclusive global coverage, MODAG not long ago secured a US patent for anle138b.

MODAG’s CEO Dr. Torsten Matthias was reportedly sanguine of the trial and said the company is on course to conduct the tests that will bring anle138b a step closer to patients. Shedding light on the relevance of attaining global patent protection for anle138b, Matthias stated that initiation of clinical testing would be a cornerstone in boosting the strategic development of the pipeline and would emphasize company’s potential to complement corporate vision and goals.

Dr. Johannes Levin, MODAG’s CMO, said that he envisages anle138b to be a tangible treatment alternative to derail MSA. Highlighting the dearth of disease-stopping treatment alternatives, he went on to add that MSA patients were being a soft target of neurodegenerative diseases, as well as balance, automatic function and progressing movement impairments. Dr. Johannes was optimistic and stated that provided Phase 1 trial would be successful, it would open door for MODAG to examine anle138b in Parkinson and other Parkinson’s disorders.

For the record, as a primary objective, the clinical trial will apparently assess the tolerability and safety of the compound in healthy volunteers. Meanwhile, the secondary objectives incorporate the assessment of the pharmacokinetic profile, along with dose-finding evaluations of both single and multiple ascending doses of anle138b. It is worth noting that anle138b will be managed orally as a single agent to healthy volunteers. Prominently, Recruitment into the trial is afoot and will be undertaken by Quotient Sciences in U.K.
 

Source credit:

https://www.businesswire.com/news/home/20191218005234/en/MODAG-Initiates-First-in-Human-Phase-1-Clinical-Trial

 



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...